Mesenchymal stem cells were affected by up-regulation of miRNA-21 in vitro

间充质干细胞在体外受到 miRNA-21 上调的影响

阅读:9
作者:Wengang Yang, Hui Zheng, Jianggui Dan, Chenxi Wang, Song Xue

Background

The expression of miRNA-21 was high in cells that were derived from MSCs, but, the role of miRNA-21in the MSCs was unknown. Material/

Conclusions

The results also suggested that, the up-regulation of miRNA-21 enhanced proliferation of MSCs, reducing the apoptosis of MSCs. MiRNA-21 promotes the differentiation of MSCs, which may pave the way for the treatment directed toward restoring miRNA-21 function for myocardial ischemia.

Methods

In this study, flow cytometry, which was used to identify the surface-associated antigens of MSCs. The 10 μmol/l 5-azacytidine was used to induce MSCs to differentiate to cardiomyocyte-like cells. Immunofluorescence, that was for detected the expression of troponin I (cTnI). The samples were assigned to 3 groups: the blank group, the miRNA-21 mimic group, and the negative control (NC) group. The proliferation of MSCs was detected by methyl thiazolylte-trazolium (MTT), the apoptosis of MSCs was analyzed by flow cytometry, Western-blot, which was used to identify the expression of cTNI and myoD in the MSCs.

Results

The proliferation of MSCs was increased, because of the over expression of miRNA-21; But, the apoptotic rate of the MSCs were slower in MIRNA-21 group, on account of the expression of miRNA-21 was higher than that of in the NC and CK groups. The expression of cTNI in miRNA-21 group was higher than that of in the NC and CK groups. Conclusions: The results also suggested that, the up-regulation of miRNA-21 enhanced proliferation of MSCs, reducing the apoptosis of MSCs. MiRNA-21 promotes the differentiation of MSCs, which may pave the way for the treatment directed toward restoring miRNA-21 function for myocardial ischemia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。